[1] Geramizadeh
B, Jalali F. Aggressive fibromatosis, clinicopathologic findings of 25 cases; a
single-center experience and review of the literature [J]. Iran J Pathol, 2017,
12(1): 20-24.
[2] Ganeshan D, Amini B, Nikolaidis P, et
al. Current update on desmoid fibromatosis [J]. J Comput Assist Tomogr,
2019,43(1):29-38. DOI: 10.1097/RCT.00000000000- 00-790.
[3] Skubitz K. Biology and treatment of
aggressive fibromatosis or desmoid tumor[J]. Mayo Clin Proc,2017,92(6):947-964.
DOI: 10.1016/j.mayocp.2017.02.012.
[4] Cărăuleanu A, Popovici RM, Costea CL, et
al. Abdominal wall endometriosis versus desmoid tumor - a challenging
differential diagnosis [J].Rom J Morphol Embryol, 2020, 61(1):45-50. DOI:
10.47162/RJME.61.1.05.
[5] 胡凤林,祁冰,张庆凯,等. 侵袭性纤维瘤病48例临床特点及诊治分析[J]. 中国实用外科杂志,2017,37(8):911-914. DOI:10.19538/j.cjps.issn1005-2208.2017.08.20.
[6] Fiore M, MacNeill A, Gronchi A, et al.
Desmoid-type fibromatosis: evolving treatment standards[J].Surg Oncol Clin N
Am, 2016,25(4):803-826. DOI: 10.1016/j.soc.2016.05.010.
[7] Martinez Trufero J, Pajares Bernad I,
Torres Ramon I, et al. Desmoid-type fibromatosis: who, when, and how to
treat[J].Curr Treat Options Oncol,2017,18(5):29. DOI:
10.1007/s11864-017-0474-0.
[8] Koskenvuo L, Ristimaki A, Lepisto A.
Comparison of sporadic and FAP-associated desmoid-type fibromatoses [J]. J Surg
Oncol,2017,116(6):716-721. DOI: 10.1002/jso.24699.
[9] 何旭昶,安文慧,曾庆彬,等. 腹内型侵袭性纤维瘤的研究进展[J]. 胃肠病学和肝病学杂志,2020,29(7):834-838.
DOI:10.3969/j.issn.1006-5709.2020.07.022.
[10] Chen X,Wang Y, Liu HY,et al. Case
report: two cases of abdominal aggressive fibromatosis that mimicked abdominal
wall endometriosis and review of literature[J]. Front Med
(Lausanne),2021,8:774235. DOI: 10.3389/fmed.2021.774235.
[11] Aitken SJ, Presneau N, Kalimuthu S, et
al. Next-generation sequencing is highly sensitive for the detection of
beta-catenin mutations in desmoid-type fibromatoses [J]. Virchows
Arch,2015,467(2):203-210. DOI: 10.1007/s00428-015-1765-0.
[12] Penel N, Chibon F, Salas S. Adult
desmoid tumors: biology, management and ongoing trials [J]. Curr Opin Oncol,
2017, 29(4):268-274. DOI: 10.1097/CCO.00000000- 00000374.
[13] Hamada S, Urakawa H, Kozawa E, et al.
Characteristics of cultured desmoid cells with different CTNNB1 mutation status
[J]. Cancer Med, 2016, 5(2): 352-360. DOI: 10.1002/cam4.582.
[14] De Marchis ML, Tonelli F, Quaresmini D,
et al. Desmoid tumors in familial adenomatous polyposis[J].Anticancer Res,
2017, 37(7): 3357-3366. DOI: 10.21873/anticanres. 11702.
[15] Koskenvuo L, Peltomäki P,
Renkonen-Sinisalo L, et al. Desmoid tumor patients carry an elevated risk of
familial adenomatous polyposis[J]. J Surg Oncol,2016,113(2):209-212. DOI:
10.1002/jso.24117.
[16] Weiss C, Angleitner-Boubenizek L,Motz
R,et al. A desmoid tumour (aggressive fibromatosis) in an 80-year-old woman –
case report of a rare differential diagnosis in gynaecology [J]. J Obstet
Gynaecol,2020, 40(1):139-140. DOI: 10.1080/01443615.2019.1588865.
[17] 洪睿霞,赵怀,罗丽,等. 侵袭性纤维瘤病的超声表现及误诊分析[J]. 中国介入影像与治疗学,2017,14(6):374-377.
DOI:10.13929/j.1672-8475.201612015.
[18] Braschi-Amirfarzan M, Keraliya AR,
Krajewski KM, et al. Role of imaging in management of desmoid-type
fibromatosis: a primer for radiologists [J]. Radiographics, 2016, 36(3):767-782.
DOI: 10.1148/rg.2016150153.
[19] 王军燕,孙延豹. 侵袭性纤维瘤病的影像学表现[J]. 医学影像学杂志,2017,27(12):2315-2318.
[20] Wang K, Zhang J, Dong M. Clinical
features and long-term outcomes of aggressive fibromatosis of the abdominal
wall after surgical resection: a retrospective study and literature review [J].
Asia Pac J Clin Oncol, 2022, 18(1):127-132. DOI: 10.1111/ajco.13525.
[21] Geramizadeh B, Jalali F. Aggressive
fibromatosis, clinicopathologic findings of 25 cases; a single-center
experience and review of the literature [J]. Iran J Pathol, 2017, 12(1):20-24.
[22] Liu X, Zong S, Cui Y, et al.
Misdiagnosis of aggressive fibromatosis of the abdominal wall: a case report
and literature review[J]. Medicine (Baltimore) ,2018, 97(10):e9925. DOI:
10.1097/MD.0000000000009925.
[23] Bulut G, Ozluk A, Erdogan AP, et al.
Pazopanib: a novel treatment option for aggressive fibromatosis[J]. Clin
Sarcoma Res, 2016, 6: 22. DOI: 10.1186/s13569-016- 0061-3.
[24] Toulmonde M, Pulido M, Ray-Coquard I, et
al. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult
patients with progressive desmoid tumours (DESMOPAZ): a non-comparative,
randomised, open-label, multicentre, phase 2 study [J]. Lancet Oncol, 2019,
20(9):1263-1272. DOI: 10.1016/S1470-2045(19)30276-1.
[25] Gounder MM, Mahoney MR, Van Tine BA, et
al. Sorafenib for advanced and refractory desmoid tumors[J]. N Engl J Med,
2018,379(25):2417-2428. DOI: 10.1056/NEJMoa1805052.
[26] 韩猛虎,景圆圆,姜合作,等. 腹壁侵袭性纤维瘤的治疗现状[J]. 中华普通外科杂志,2019,34(7):643-646.
DOI:10.3760/cma.j.issn.1007-631X.2019.07.032.
[27] 公佩涛,揭志刚,李正荣,等. 盆腔巨大孤立性纤维性肿瘤一例[J]. 中华普通外科杂志,2017,32(8):690.
DOI:10.3760/cma.j.issn.1007-631X.2017.08.017.
[28] Timbergen MJM, Schut AW, Grünhagen DJ,
et al. Active surveillance in desmoid-type fibromatosis: a systematic
literature review [J]. Eur J Cancer, 2020, 137: 18-29. DOI:
10.1016/j.ejca.2020.06.022.
|